Integra Stock Dips on Lowered Guidance After Q3 Sales Miss
Integra LifeSciences (Nasdaq: IART) shares fell after reporting third-quarter results that missed consensus forecasts.
Shares of IART dropped over 8% to $14.15 after the market opened. The company reported a loss of $5.4 million, or 7¢ per share, on sales of $402.1 million.
Integra saw a 50% bottom-line gain and a 5.6% sales increase. Adjusted earnings per share were 54¢, exceeding Wall Street expectations by 11¢.
However, sales fell short of forecasts due to "supply interruptions." The Codman Specialty Surgical business generated around 70% of revenue, at $292 million.
No comment from the company on the sales miss.
Author's summary: Integra LifeSciences' stock dips due to lowered guidance.
- Loss: $5.4 million
- Earnings per share: 7¢
- Sales: $402.1 million
- Adjusted earnings per share: 54¢
More News
- Filmmaker Tamara Stepanyan Leads Masterclass at Armenian Film Society - The Armenian Mirror-Spectator
- Distorted narratives risk reversing South Caucasus peace progress [OPINION]
- Half of Illinois students reading at grade level, fewer in math under loosened standards
- Armenia’s Grisha Martirosyan among Operalia 2025 winners - The Armenian Mirror-Spectator
- Shares of Navan Down 16% In Long-Awaited IPO Debut
- Flau’jae Johnson Shuts Down Governor’s Call for Charlie Kirk Statue at LSU, Social Media Rides With Her
- Wayfarers accessibility project aims to create new pathways for outdoor recreation
- Reversing course: Spotsylvania Board of Supervisors reduce recommended data center setbacks - Fredericksburg Free Press
- Lawyers Petition UN Working Group on Arbitrary Detention to Order Immediate Release of Vicken Euljekjian - The Armenian Mirror-Spectator
- Somalia’s Entry into the East African Community: Gains and Setbacks – Puntland Post